Table 1.
Baseline characteristics of the participants.
| Variable | Values |
|---|---|
| Age, y | 65.3 ± 6.2 |
| Gender, n (%) | |
| Women | 12 (36.4%) |
| Men | 21 (63.6%) |
| BMI, kg/m2 | 32.6 ± 4.2 |
| LDL cholesterol, mg/dL | 118 ± 34.4 |
| HDL cholesterol, mg/dL | 50.2 ± 12.9 |
| Total cholesterol, mg/dL | 192 ± 39.3 |
| Triglycerides, mg/dL | 120 ± 72.2 |
| Cardiovascular Risk factors, n (%) | |
| Current smokers | 6 (18.2%) |
| Family history of premature CHD | 6 (19.4%) |
| Obesity (BMI ≥ 25kg/m2) | 32 (97.0%) |
| Type 2 Diabetes | 13 (39.4%) |
| Hypertension | 28 (84.8%) |
| High LDL cholesterol (>130 mg/dL) | 25 (75.6%) |
| Low HDL cholesterol (<40 mg/dL for men or <50 mg/dL for women) | 8 (24.2%) |
| Medications, n (%) | |
| Alfa blockers | 2 (6.1%) |
| Beta blockers | 6 (18.2%) |
| ACE inhibitors | 14 (42.4%) |
| Angiotensin II receptor antagonists | 11 (33.3%) |
| Diuretics | 13 (39.4%) |
| Statins | 16 (48.5%) |
| Oral hypoglycemic drugs | 12 (36.4%) |
| Acetylsalicylic acid | 10 (30.3%) |
Data presented as mean ± SD or n (%) (n = 33). BMI, body mass index; LDL, low density lipoproteins; HDL, high density lipoproteins; CHD, coronary heart disease.